Macrocylic compounds as ROS1 kinase inhibitors
Methods for inhibiting a ROS1 kinase with compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R 2 , R 2a , R 3 , R 3a , and Z are as defined herein. The compounds and methods provided herein are useful in the treatment of cancer (e.g., ROS1-associated cancers as defined herein).
1. A method for treating a ROS1-associated cancer in a subject in need thereof, wherein the subject has been administered a first TRK inhibitor that is entrectinib, and the ROS1-associated cancer has developed resistance to the first TRK inhibitor, the method comprising administering
(6R,15R)-9-fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.02,6.07,12.021,25]pentacosa-1(24),7,9,11,18(25),19,22-heptaen-17-one;
or a pharmaceutically acceptable salt thereof;
wherein the ROS1-associated cancer is selected from non-small-cell lung cancer or papillary thyroid carcinoma and has a point mutation in the ROS1 gene results in the production of a ROS1 kinase having one or more amino acid substitutions selected from the group consisting of A15G, R118N, A122T, R245I, G1025R, S1186F, P1539S, T1735M, R1948H, D2033Y, R2072N, R2162W, R2162Q, R2162L, and E2308W.
2. The method of claim 1 , wherein the cancer further comprises one or more chromosome translocations or inversions resulting in a ROS1 gene fusion.
3. The method of claim 2 , wherein the ROS1 gene fusion is selected from the group consisting of: CD74-ROS1, SLC34A2-ROS1, TPM3-ROS1, SDC4-ROS1, EZR-ROS1, LRIG-ROS1, KDELR2-ROS1, CCDC6-ROS1, FIG-ROS1, TPD52L1-ROS1, CEP85L-ROS1, ZCCHC8-ROS1, CCDC30-ROS1, TFG-ROS1, TMEM106B-ROS1, YWHAE-ROS1, MSN-ROS1, PWWP2A-ROS1, FYN-ROS1, MKX-ROS1, PPFIBP1-ROS1, ERC1-ROS1, MY05A-ROS1, CLIP1-ROS1, HLA-A-ROS1, KIAA1598-ROS1, CLTC-ROS1, LIMA1-ROS1, NFkB2-ROS1, NCOR2-ROS1, KCL1-ROS1, and TBL1XR1-ROS1.